🍽️ dehydrocholic acid non-drug

AI Engines For more Details: PerplexityKagi LabsYou

  1. Bile Acid Function: Dehydrocholic acid is one of the primary bile acids produced in the liver and stored in the gallbladder. Bile acids, including dehydrocholic acid, play essential roles in emulsifying dietary fats, facilitating lipid digestion, and promoting the absorption of fat-soluble vitamins and nutrients in the small intestine.

  2. Gallstone Dissolution: Dehydrocholic acid has been investigated for its potential therapeutic use in the dissolution of gallstones, particularly cholesterol gallstones. By increasing the solubility of cholesterol in bile, dehydrocholic acid may help dissolve cholesterol gallstones and prevent their recurrence. However, the use of dehydrocholic acid for this purpose has largely been supplanted by other treatments, such as oral bile acid therapy with ursodeoxycholic acid (UDCA) or surgical interventions.

  3. Sodium Deoxycholate Derivative: While dehydrocholic acid itself is not widely used as a therapeutic agent, its sodium salt, sodium deoxycholate, has been employed for various medical and cosmetic purposes. Sodium deoxycholate is known for its detergent and solubilizing properties and has been utilized in the treatment of subcutaneous fat deposits through injection lipolysis procedures.

  4. Injection Lipolysis: Sodium deoxycholate injections have been used off-label for nonsurgical fat reduction and body contouring, particularly in the treatment of localized adiposity, such as submental fat (double chin) and small pockets of fat on the body. The injections are typically administered directly into the targeted fat deposits, where sodium deoxycholate disrupts fat cell membranes, leading to cellular breakdown and eventual elimination of fat.

  5. Adverse Effects: While injection lipolysis with sodium deoxycholate may offer cosmetic benefits, it is associated with potential adverse effects, including pain, swelling, bruising, redness, and induration at the injection site. In some cases, more serious complications, such as skin necrosis, nerve injury, and contour irregularities, may occur. Therefore, the procedure should be performed by trained healthcare professionals in appropriate clinical settings, and patients should be informed of the potential risks and benefits.

  6. Regulatory Status: The use of sodium deoxycholate injections for cosmetic purposes is subject to regulatory oversight in many countries. Providers offering injection lipolysis procedures should adhere to applicable regulations and guidelines to ensure patient safety and quality of care.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of dehydrocholic acid non-drug On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by dehydrocholic acid non-drug

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Bacteroides genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Clostridioides genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Lacrimispora genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Enterocloster genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens C no rank Decreases 👶 Source Study
Clostridium perfringens CPE no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Clostridium perfringens B no rank Decreases 👶 Source Study
Clostridium perfringens E no rank Decreases 👶 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Bifidobacterium longum species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Akkermansia massiliensis species Decreases 👶 Source Study
Candidatus Akkermansia intestinavium species Decreases 👶 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Akkermansia muciniphila species Decreases 📓 Source Study High Levels linked to long-lived individuals
Roseburia hominis species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suis subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study

Impact of dehydrocholic acid non-drug on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.4 0.4
Acne 0.3 0.8 -1.67
ADHD 3.5 0.3 10.67
Age-Related Macular Degeneration and Glaucoma 1.1 0.4 1.75
Allergic Rhinitis (Hay Fever) 2.2 2.3 -0.05
Allergies 3.4 2.1 0.62
Allergy to milk products 1 1 0
Alopecia (Hair Loss) 1.3 1.3
Alzheimer's disease 3.8 3.8 0
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.5 0.2 6.5
Ankylosing spondylitis 2.6 0.6 3.33
Anorexia Nervosa 1.3 1.7 -0.31
Antiphospholipid syndrome (APS) 0.4 0.3 0.33
Asthma 3.9 2.4 0.63
Atherosclerosis 1.2 1.1 0.09
Atrial fibrillation 2.3 1.3 0.77
Autism 5.9 5.6 0.05
Autoimmune Disease 0.6 1 -0.67
Barrett esophagus cancer 0.6 0.3 1
benign prostatic hyperplasia 0.3 -0.3
Biofilm 1.5 1.5
Bipolar Disorder 1.2 0.8 0.5
Brain Trauma 0.9 1.1 -0.22
Breast Cancer 0.3 0.3
Cancer (General) 0.9 2.3 -1.56
Carcinoma 3.4 2.3 0.48
Celiac Disease 1.2 3.4 -1.83
Cerebral Palsy 1.5 1 0.5
Chronic Fatigue Syndrome 2.1 3 -0.43
Chronic Kidney Disease 3.3 1.7 0.94
Chronic Lyme 0.7 0.8 -0.14
Chronic Obstructive Pulmonary Disease (COPD) 1.5 1.4 0.07
Chronic Urticaria (Hives) 0.8 0.2 3
Coagulation / Micro clot triggering bacteria 0.7 1 -0.43
Cognitive Function 2.9 1.6 0.81
Colorectal Cancer 6.1 1.6 2.81
Constipation 0.3 0.7 -1.33
Coronary artery disease 0.6 1.5 -1.5
COVID-19 4.5 4.4 0.02
Crohn's Disease 4.9 3.5 0.4
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 1.6 -1.6
deep vein thrombosis 1.1 1.1 0
Denture Wearers Oral Shifts 1 1
Depression 7.5 5.5 0.36
Dermatomyositis 0.3 0.3 0
Eczema 1.1 1.1 0
Endometriosis 2 1.1 0.82
Eosinophilic Esophagitis 0.3 0.6 -1
Epilepsy 2 1.5 0.33
erectile dysfunction 1.1 0.3 2.67
Fibromyalgia 2.5 0.8 2.13
Functional constipation / chronic idiopathic constipation 2.6 2.7 -0.04
gallstone disease (gsd) 1.6 1.2 0.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.8 0.5 0.6
Generalized anxiety disorder 1.1 2.4 -1.18
giant cell arteritis 0.2 -0.2
Glioblastoma 0.3 -0.3
Gout 1.7 0.3 4.67
Graves' disease 1.6 2.7 -0.69
Gulf War Syndrome 0.6 0.7 -0.17
Halitosis 1.4 0.3 3.67
Hashimoto's thyroiditis 3 1.5 1
Heart Failure 2.1 1.1 0.91
hemorrhagic stroke 1.3 1.3
Hidradenitis Suppurativa 1.2 0.3 3
High Histamine/low DAO 1 0.3 2.33
hypercholesterolemia (High Cholesterol) 0.5 0.2 1.5
hyperglycemia 1 1.5 -0.5
Hyperlipidemia (High Blood Fats) 1 0.3 2.33
hypersomnia 0.7 -0.7
hypertension (High Blood Pressure 3.1 3.6 -0.16
Hypothyroidism 0.1 0.4 -3
Hypoxia 2.2 0.3 6.33
IgA nephropathy (IgAN) 1.3 1.9 -0.46
Inflammatory Bowel Disease 4.4 5 -0.14
Insomnia 1.6 1.9 -0.19
Intelligence 0.5 0.5
Intracranial aneurysms 1.1 0.6 0.83
Irritable Bowel Syndrome 4.6 3.1 0.48
ischemic stroke 2.5 0.8 2.13
Liver Cirrhosis 4.7 4 0.18
Long COVID 3.6 4.8 -0.33
Low bone mineral density 0.5 -0.5
Lung Cancer 0.6 1 -0.67
Mast Cell Issues / mastitis 0.5 0.3 0.67
ME/CFS with IBS 0.7 0.8 -0.14
ME/CFS without IBS 0.5 1.6 -2.2
membranous nephropathy 0.3 0.3
Menopause 1.4 0.7 1
Metabolic Syndrome 4.8 5.9 -0.23
Mood Disorders 7.8 4.1 0.9
multiple chemical sensitivity [MCS] 0.7 0.1 6
Multiple Sclerosis 4.5 2.9 0.55
Multiple system atrophy (MSA) 1.3 0.4 2.25
myasthenia gravis 0.3 0.7 -1.33
neuropathic pain 2.2 -2.2
Neuropathy (all types) 0.5 1.2 -1.4
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 3.3 3.1 0.06
NonCeliac Gluten Sensitivity 1.2 0.6 1
Obesity 7 6 0.17
obsessive-compulsive disorder 2.2 2.6 -0.18
Osteoarthritis 1.2 1 0.2
Osteoporosis 1.3 1.5 -0.15
pancreatic cancer 0.8 0.3 1.67
Parkinson's Disease 5.2 3.5 0.49
Polycystic ovary syndrome 3 2.4 0.25
Postural orthostatic tachycardia syndrome 0.2 0.3 -0.5
Premenstrual dysphoric disorder 0.7 0.4 0.75
primary biliary cholangitis 1.2 1.1 0.09
Primary sclerosing cholangitis 2.9 1.3 1.23
Psoriasis 1.4 1.9 -0.36
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.3 3.2 0.34
Rosacea 0.8 1 -0.25
Schizophrenia 5 2.3 1.17
scoliosis 0.3 -0.3
Sjögren syndrome 1.9 2.1 -0.11
Sleep Apnea 1.3 1 0.3
Slow gastric motility / Gastroparesis 0.6 0.3 1
Small Intestinal Bacterial Overgrowth (SIBO) 1.4 0.7 1
Stress / posttraumatic stress disorder 2.7 2.1 0.29
Systemic Lupus Erythematosus 2.5 1.6 0.56
Tic Disorder 0.6 1.2 -1
Tourette syndrome 1 0.3 2.33
Type 1 Diabetes 1.8 3 -0.67
Type 2 Diabetes 4.4 4.5 -0.02
Ulcerative colitis 3.3 3.8 -0.15
Unhealthy Ageing 3.6 1.7 1.12
Vitiligo 1.3 1 0.3

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]